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Summary
Background The low prevalence of allergic disease in the rural tropics has been attributed to
the protective effects of chronic helminth infections. There is concern that treatment-based
control programmes for these parasites may lead to an increase in the prevalence of allergic
diseases.
Objective We measured the impact of 15–17 years of anthelmintic treatment with ivermectin
on the prevalence of allergen skin test reactivity and allergic symptoms in school-age
children.
Methods The prevalence of allergen skin test reactivity, exercise-induced bronchospasm and
allergic symptoms was compared between school-age children living in communities that had
received community-based treatments with ivermectin (for onchocerciasis control) for a
period of 15–17 years with those living in geographically adjacent communities that had
received no ivermectin.
Results The prevalence of allergen skin test reactivity was double in children living in treated
communities compared with those in untreated communities (16.7% vs. 8.7%, adjusted OR
2.10, 95% CI 1.50–2.94, Po0.0001), and the effect was mediated partly by a reduced
prevalence of Trichuris trichiura among treated children. Ivermectin treatments were
associated with an increased prevalence of recent eczema symptoms (adjusted OR 2.24, 95%
CI 1.05–4.78, P=0.04) but not symptoms of asthma or rhino-conjunctivitis. The effect on
eczema symptoms was not associated with reductions in geohelminth infections.
Conclusion Long-term periodic treatments with ivermectin were associated with an increased
prevalence of allergen skin test reactivity. There was some evidence that treatment was
associated with an increased prevalence of recent eczema symptoms but not those of asthma
or rhino-conjunctivitis.
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Introduction
The prevalence of allergic diseases appears to be low in
rural areas of developing countries [1, 2]. In such areas,
poverty and the inadequate disposal of faeces are com-
monplace and there is a high prevalence of geohelminth
infections [3]. Geohelminth parasites are estimated to
infect 3.8 billion humans world-wide [4], and WHO has
endorsed the control of these infections through the
provision of periodic treatments with anthelmintic drugs
to high-risk groups particularly schoolchildren [4].
Several epidemiologic studies have provided evidence
for an inverse association between geohelminth infections
and allergen skin test reactivity in areas where these
infections are highly endemic [5–8] and it has been
suggested that geohelminths may suppress allergy in
these populations [6, 9]. This has raised the concern that
the mass treatment of helminth infections through an-
thelmintic treatment programmes may increase the
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infections are endemic.
Intervention studies of periodic anthelmintic treatment
have provided conﬂicting evidence with three studies
showing an increased risk of allergen skin test reactivity
after treatment [10–12] and one study showing no effect
on allergen skin test reactivity or allergic disease [13]. The
negative study provided treatment for 12 months while
the other three studies with positive ﬁndings provided
treatment for between 12 and 30 months.
An opportunity to study the long-term effects of
anthelmintic treatment on allergy was provided by a
control programme for onchocerciasis that has been
treating endemic communities with the broad-spectrum
anthelmintic drug ivermectin at annual or semi-annual
intervals for the past 15–17 years [14]. Because ivermectin
also has potent activity against geohelminths [15], we
investigated the impact of long-term ivermectin treat-
ments on allergen skin test reactivity and allergic disease
by comparing the prevalence of these parameters in
children living in communities that had received mass
treatments with ivermectin with children living in geo-
graphically adjacent communities that had never received
ivermectin treatments.
Methods
Study population and design
The study was conducted between March 2005 and April
2007 in the Districts of Eloy Alfaro and San Lorenzo in the
northern coastal Province of Esmeraldas, Ecuador [16].
Most communities were located along rivers in a tropical
rain forest area at altitudes below 100m above sea level.
Greater than 90% of the population in each study com-
munity was Afro-Ecuadorian. The main economic activ-
ities are agriculture, logging, ﬁshing and the extraction of
African Palm oil. Poorly developed infrastructure, un-
treated sewage and rudimentary solid waste disposal are
common characteristics of most communities. All chil-
dren aged 6–16 years in the communities were eligible to
participate. Updated censuses from all communities were
used as the basis for recruitment. Informed written con-
sent was obtained from the child’s parents or guardian.
The study protocol was approved by the Ethics Committee
of the Hospital Pedro Vicente Maldonado, Ecuador.
Selection of communities
Treated communities were selected according to the treat-
ment schedule of the Ecuadorian Onchocerciasis Elimina-
tion Programme (EOEP). Non-treated communities were
selected from maps of the study area and consisted of
geographically adjacent communities selected to be as
similar as possible with respect to size, ethnicity, and
socio-economic characteristics. Onchocerca volvulus in-
fection was never present in non-treated communities and
none have received mass ivermectin treatment. The pre-
valence of O. volvulus infection in treated communities
before the introduction of ivermectin was 440% in adults
but lower in children [17]. No other ﬁlarial helminth
infections were present in the study area [18].
Ivermectin treatment
Twice-annual community treatments with ivermectin
were initiated between 1991 and 1992. The second annual
dose was suspended in 1995–1996 and then reintroduced
from 1998. Eligibility criteria for treatment are: weight
415kg and free of serious illness (e.g. active tuberculosis,
terminal cancer, etc.), and for women, not pregnant
and not nursing infants up to 3 months of age. Distribu-
tion was organized by community health workers and
single-dose treatments of 150mg/kg ivermectin were ob-
served directly. The annual treatment coverage of the
programme was 85.2% (range 54.9–97.9%) over the 15-
year period [14].
Subject evaluations
A questionnaire modiﬁed from the ISAAC Phase II ques-
tionnaire [16] was administered to the child’s mother or
guardian to collect information on allergic symptoms and
other relevant data. A stool sample was collected and
analysed for the presence of eggs and larvae by the
modiﬁed Kato–Katz and formol-ethyl acetate concentra-
tion methods [19]. Skin reactivity was tested to house dust
mite (HDM) (Dermatophagoides pteronyssinus; Greer
Laboratories, Lenoir, NC, USA), grass pollen mix (Greer
Laboratories), American cockroach (Periplaneta ameri-
cana; Greer Laboratories), fungi mix (Greer Laboratories),
Alternaria tenuis (Greer Laboratories), cat (Greer Labora-
tories) and dog (Greer Laboratories) extracts. Allergens
and positive histamine and negative saline controls were
pricked onto the volar surface of the forearm, and reac-
tions were recorded after 15min. A reaction was consid-
ered positive if the mean diameter was X3mm greater
than the negative control. All tests were conducted by the
same observer (M. V.). Exercise-induced bronchospasm
(EIB) was performed in a subgroup of 2040 children, 437
(21.4%) from non-treated and 1603 children (78.6%) from
treated communities. Peak expiratory ﬂow rate (PEFR)
was measured before and after 6min of vigorous exercise
as described previously [13].
Statistical analysis
Allergen skin test reactivity was deﬁned as a positive skin
test reaction to any allergen. Recent wheeze was classiﬁed
as wheeze within the previous 12 months; recent rhino-
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panied by itchy eyes within the previous 12 months; recent
eczema symptoms as the presence of an itchy skin condi-
tion affecting the ﬂexures within the previous 12 months;
and EIB as a 15% or greater fall in PEFR after exercise.
Analyses were performed using multiple logistic regression
models allowing for clustering using robust standard
errors. Age, sex, monthly household income, maternal
educational level and water source were included as a
priori confounders in all models. Other potential confoun-
derswereincludedintheﬁnalmodelifinclusionalteredOR
by 410%. Interactions were assessed using the Wald test.
Because all children in the treated communities had re-
ceived at least one dose of ivermectin, we could not do a
separate analysis of the effects of treatment in the treated
communities. Analyses were performed using STATA 10
(StataCorp, College Station, TX, USA).
Results
Study population
A total of 3901 children were assessed, 2070 children from
27 non-treated and 1831 children from 31 treated com-
munities. The mean cluster size was 76.7 (range 17–224)
and 59.1 (range 14–223) in non-treated and treated
communities, respectively. Results of allergen skin prick
tests were available for 1983 (95.8%) and 1782 (97.4%)
from non-treated and treated children and stool samples
were collected from 1953 (94.3%) and 1794 (97.8%) of
non-treated and treated children, respectively.
Demographic, socio-economic and environmental
characteristics of the study children are shown in Table 1
and show differences between treated and non-treated
children with respect to several characteristics.
EOEP has achieved extremely high rates of coverage
with ivermectin in the study communities over the past
15–17 years [15]. All children living in treated commu-
nities had received at least one dose of ivermectin and
79.3% had received 475% of designated treatments over
the previous 5 years. Reported treatments with other
anthelmintic drugs by parental questionnaire were similar
among children from both treated (77.5%) and non-treated
(78.7%) communities over the previous 6 months. Most
treatments were bought directly by parents, were distrib-
uted through schools, or through doctor consultations.
During the period of this study, there were no systematic
programmes ofperiodictreatmentswithother anthelmintic
drugs suchas albendazole inany ofthe study communities.
The prevalence of any geohelminth infection was great-
er among non-treated children (86.2% vs. 62.7%), largely
attributable to a higher prevalence of Trichuris trichiura
infection (81.5% vs. 31.2%) (Table 1). There was no
difference in the prevalence of Ascaris lumbricoides
between treated and non-treated children (48.7% vs.
57.3%), and surprisingly, the prevalence of hookworm
was greater in treated than in non-treated children (14.6%
vs. 3.9%). Infection intensities with A. lumbricoides did
not differ signiﬁcantly between treatment groups [geo-
metric mean (GM) infection intensities, untreated 34 eggs
per gram (epg) vs. treated 30epg, P=0.61] but the in-
tensity of T. trichiura was signiﬁcantly greater in un-
treated children (GM infection intensities, untreated
132epg vs. treated 44epg, Po0.0001).
Treatment area and allergic parameters
The effect of treatment on allergic parameters is showed in
Table 2. Children living in treated communities had a
greater prevalence of allergen skin test reactivity (SPT1)
(16.7%) compared with those living in untreated commu-
nities (8.7%) (adjusted OR 2.10, 95% CI 1.50–2.94,
Po0.0001). The prevalence of recent wheeze symptoms,
rhino-conjunctivitis and EIB did not differ signiﬁcantly
between treated and non-treated children, but treated
children had a higher prevalence of recent eczema symp-
toms than non-treated children (adjusted OR 2.24, 95% CI
1.05–4.78, P=0.04). The prevalence of SPT1 was greater
in 11 of 31 treated communities than in any of the non-
treated community (Fig. 1), but no patterns were observed
for the other allergic parameters (data not shown).
Effect of geohelminth prevalence on the association
between treatment area and SPT1
The effect of treatment on SPT1 was explored in hier-
archical analyses by examining whether the association
between treatment and SPT1 might be explained by
reductions in geohelminth prevalence. To investigate this,
the effect on the association between treatment area and
SPT1 of inclusion of each of A. lumbricoides, T. trichiura
and hookworm was assessed either separately or simulta-
neously in the model. A reduction in OR will occur if the
geohelminth is a mediating factor in the causal pathway
between treatment and skin test reactivity. The only
helminth that reduced the OR between treatment area
and SPT1 was T. trichiura (change of OR from 2.10 to
1.69) (Table 3). A. lumbricoides and hookworm had
negligible effects. Sequential addition of geohelminths to
the model showed a strong effect only when T. trichiura
was included in the model (Table 3). A similar analysis for
the association between treatment area and eczema symp-
toms did not show effects for any of the geohelminth
parasites (Table 3).
Geohelminth infections and allergic parameters
SPT1. Infection with any geohelminth was signiﬁcantly
inversely associated with SPT1 (OR 0.71, 95% CI
 c 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40:1669–1677
Anthelmintics increase allergen skin test reactivity 16710.55–0.91, P=0.007). This effect appeared to be explained
by a strong inverse association between skin test reactiv-
ity and T. trichiura infection (OR 0.72, 95% CI 0.58–0.90,
P=0.01) – neither A. lumbricoides nor hookworm infec-
tions were signiﬁcantly inversely associated with SPT1.
There was evidence for an inverse association between
Table 1. Characteristic of children living in non-treated and treated communities
Children living in non-treated communities Children living in treated communities P-value
Age (years)
6–7 312/2070 (15.1) 272/1831 (14.9)
8–9 487/2070 (23.5) 435/1831 (23.8)
10–11 471/2070 (22.7) 418/1831 (22.8)
12–13 486/2070 (23.5) 391/1831 (21.3)
14–16 314/2070 (15.2) 315/1831 (17.2) 0.26
Sex
Male 1043/2070 (50.4) 983/1831 (53.7)
Female 1027/2070 (49.6) 848/1831 (46.3) 0.04
Socio-economic indicators
Maternal education
Illiterate 245/2060 (11.9) 261/1831 (14.2)
Some or full primary 1170/2060 (56.8) 1155/1831 (63.1)
Some or full secondary 529/2060 (25.7) 337/1831 (18.4)
Some or full superior 46/2060 (2.2) 51/1831 (2.8)
Don’t know 70/2060 (3.4) 27/1831 (1.5) 0.008
GM income (range) USD 75.2 (71.1–19.6) 41.1 (39.0–43.3) o0.0001
Electrical appliances
0–1 746/2070 (36) 1142/1831 (62.4)
Two or more 1324/2070 (64) 689/1831 (37.6) o0.0001
Environmental indicators
Water source
Piped 105/2070 (5.1) 15/1831 (0.8)
Well 59/2070 (2.9) 12/1831 (0.7)
River and rain 549/2070 (26.5) 1533/1831 (83.7)
Piped and river and rain 618/2070 (29.9) 192/1831 (10.5)
Well and river and rain 684/2070 (33.0) 73/1831 (4.0)
Other combinations 55/2070 (2.7) 6/1831 (0.3) o0.0001
Bathroom appliance
Latrine 1139/2070 (55) 1172/1829 (64.1)
WC 21/2070 (1) 94/1829 (5.1)
Field 900/2070 (43.5) 557/1829 (30.5)
Other 10/2070 (0.5) 6/1829 (0.3) 0.1
Geohelminth infections
Any 1684/1953 (86.2) 1124/1794 (62.7) o0.0001
Ascaris lumbricoides GM 33.7 (28–40.6) 30 (24.3–37) 0.61
Prevalence 1119/1953 (57.3) 873/1794 (48.7) 0.26
Trichuris. trichiura GM 132.1 (114.9–151.8) 3.9 (3.4–4.6) o0.0001
Prevalence 1591/1953 (81.5) 560/1794 (31.2) o0.0001
Hookworm
Prevalence 76/1953 (3.9) 262/1794 (14.6) o0.0001
Recent anthelmintic treatment (last 6 months)
Yes 1583/2043 (77.5) 1439/1828 (78.7)
No 299/2043 (14.6) 218/1828 (11.9)
Don’t know 161/2043 (7.9) 171/1828 (9.4) 0.39
SPT
Any allergen 172/1983 (8.7) 298/1782 (16.7) o0.0001
HDM 104/1983 (5.2) 146/1782 (8.2) o0.0001
Cockroach 57/1983 (2.9) 104/1782 (4.3) 0.001
Others 34/1983 (1.7) 121/1782 (6.8) o0.0001
Other allergens included grass pollen mix, fungi mix, Alternaria tenuis, cat and dog.
GM, geometric mean (eggs per gram of faeces).
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SPT1: OR 0.75 (95% CI 0.60–0.93, P=0.01) for light
infections and OR 0.50 (95% CI 0.35–0.70, Po0.0001) for
the moderate to heavy intensity infections, compared with
non-infected children (Table 4).
Wheeze, rhino-conjunctivitis, eczema symptoms and
EIB. The prevalence and intensities of A. lumbricoides,
T. trichiura and hookworm infections were not associated
with symptoms of recent wheeze, rhino-conjunctivitis and
eczema or with EIB.
SPT1 and allergic symptoms
There were weak non-signiﬁcant associations between
SPT1 and recent wheeze (adjusted OR 1.29, 95% CI
0.96–1.74, P=0.09), EIB (adjusted OR 1.32, 95% CI
0.84–2.08, P=0.23), and recent eczema symptoms (ad-
justed OR 1.35, 95% CI 0.87–2.12, P=0.18), but no
association with recent rhino-conjunctivitis (adjusted OR
0.97, 95% CI 0.65–1.43, P=0.87). Treatment did not
modify these effects.
Discussion
The present study examined the effect of long-term
periodic treatments with a broad-spectrum anthelmintic
drug, ivermectin, on the prevalence of allergy in school-
age children living in communities in a rural tropical area
of Ecuador. To perform this, we compared the prevalence
of allergen skin test reactivity and other parameters of
clinical allergy between children who lived in commu-
nities that had received ivermectin annually or semi-
annually for a period of 15–17 years with children living
in communities that had never received ivermectin treat-
ment. The data provide evidence that long-term anthel-
mintic treatment may be accompanied by an increase in
the prevalence of allergen skin test reactivity and perhaps
recent eczema symptoms but no evidence for effects on
asthma or rhinitis symptoms.
Strengths of the study are the objective documentation
of allergen skin test reactivity, exercise-induced bronch-
ospasm, and geohelminth infections using standardized
protocols. Because the study was conducted over a 2-year
period, seasonal differences (i.e. dry vs. rainy season) in
rates of skin sensitization could have biased the ﬁndings;
however, an analysis of skin test reactivity by month
showed no evidence for seasonal differences in allergen
skin test reactivity (data not shown). A high proportion of
Table 2. Effect of the treatment on allergen skin test reactivity (SPT), exercise-induced bronchospasm (EIB), and symptoms of recent wheeze, rhino-
conjunctivitis and eczema
Children N Prevalence (%) Crude OR P-value Adjusted OR P-value
SPT
Living in non-treated communities 1983 172 (8.7) 1 1
Living in treated communities 1782 298 (16.7) 2.11 (1.61–2.78) o0.0001 2.10 (1.50–2.94) o0.0001
Wheeze
Living in non-treated communities 2068 231 (11.2) 1 1
Living in treated communities 1831 175 (9.6) 0.78 (0.62–0.99) 0.04 0.84 (0.62–1.13) 0.3
EIB
Living in non-treated communities 437 39 (8.9) 1 1
Living in treated communities 1603 91 (5.7) 0.61 (0.31–1.21) 0.16 1.0 (0.50–1.99) 0.9
Rhino-conjunctivitis symptoms
Living in non-treated communities 2070 143 (6.9) 1 1
Living in treated communities 1831 100 (5.5) 0.72 (0.52–0.99) 0.05 0.70 (0.46–1.08) 0.11
Eczema symptoms
Living in non-treated communities 2068 66 (3.2) 1 1
Living in treated communities 1830 120 (6.6) 1.62 (0.98–2.70) 0.06 2.24 (1.05–4.78) 0.04
ORadjustments are:all– age,sex, income, maternaleducationallevelandwater source;wheeze –cookingmaterials;eczemasymptoms–timewatching
TVand maternal history of allergic disease. EIB was deﬁned by a 15% fall in PEFR after exercise compared to before exercise.
Fig. 1. Prevalence of allergen skin test reactivity (SPT1) by community
for those treated (black bars) and not treated (grey bars) with ivermectin.
 c 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40:1669–1677
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other anthelmintic treatments during the previous 6
months – these treatments were generally purchased
directly by parents from pharmacies and such treatments
were not associated with any of the study outcomes (data
not shown). We have shown previously that such sporadic
and short-term treatments are not associated with SPT [6].
Treatment contamination of the untreated communities, if
such treatment were to mediate an effect, would be
expected to increase the prevalence of SPT in untreated
communities and reduce the estimate of effect. Deﬁnitions
of clinical allergy including eczema were questionnaire
based and used standardized deﬁnitions [16]. Question-
naire data could have been associated with possible biases
– observation bias because treatment allocation was not
concealed and recall bias because the educational levels of
the primary respondents to the questionnaires, the
mothers, differed by treatment group. Several environ-
mental and socio-economic factors differed between the
treated and untreated communities. Although we
controlled for these differences by treatment area in
the analysis, residual confounding or systematic bias
cannot be excluded. However, ORs were stable with
respect to controlling for confounding suggesting that
these estimates may not be subject to signiﬁcant con-
founding.
Table 3. Effects of individual or sequential adjustments for geohelminth infections on the associations between treatment and allergen skin test
reactivity or eczema symptoms
Adjusted OR P-value Adjusted OR P-value
Individually added to the model Sequentially added to the model
Adjusted OR (of treatment area on atopy)=2.10 (1.50–2.94) Po0.0001
Ascaris lumbricoides 2.03 (1.46–2.82) o0.0001 A. lumbricoides 2.03 (1.46–2.82) o0.0001
Trichuris trichuria 1.69 (1.21–2.37) o0.02 Add T. trichuria 1.59 (1.15–2.20) o0.005
Hookworm 2.12 (1.50–2.99) o0.0001 Add hookworm 1.57 (1.13–2.19) 0.007
Adjusted OR (of treatment area on eczema symptoms)=2.24 (1.05–4.78) Po0.04
A. lumbricoides 2.30 (1.09–4.86) 0.03 A. lumbricoides 2.30 (1.09–4.86) 0.03
T. trichuria 2.36 (1.11–5.04) 0.03 Add T. trichuria 2.26 (1.05–4.87) 0.04
Hookworm 2.29 (1.08–4.86) 0.03 Add hookworm 2.20 (0.99–4.85) 0.05
Table 4. Association between allergen skin test reactivity (SPT) and geohelminth infections
N SPT (%) Crude OR P-value Adjusted OR P-value
Ascaris lumbricoides
Negative 1713 242 (14.1) 1 1
Positive 1950 220 (11.3) 0.77 (0.59–1.0) 0.06 0.87 (0.67–1.12) 0.27
Intensity (epg)
Negative 2095 300 (14.3) 1 1
Light (1–4999epg) 807 86 (10.7) 0.71 (0.53–0.96) 0.03 0.77 (0.58–1.02) 0.07
Moderate (5000–49999epg) 654 64 (9.8) 0.65 (0.43–0.97) 0.04 0.70 (0.49–1.0) 0.05
Heavy (450000epg) 107 12 (11.2) 0.76 (0.44–1.29) 0.31 0.85 (0.47–1.55) 0.60
Trichuris trichiura
Negative 1562 260 (16.7) 1 1
Positive 2101 202 (9.6) 0.53 (0.43–0.67) o0.0001 0.72 (0.58–0.90) 0.01
Intensity (epg)
Negative 1730 284 (16.4) 1 1
Light (1–999epg) 1313 139 (10.6) 0.60 (0.47–0.77) o0.0001 0.75 (0.60–0.93) 0.01
Moderate-heavy (41000epg) 620 39 (6.3) 0.34 (0.24–0.49) o0.0001 0.50 (0.35–0.70) o0.0001
Hookworm
Negative 3332 415 (12.5) 1 1
Positive 331 47 (14.2) 1.16 (0.75–1.80) 0.5 0.94 (0.59–1.48) 0.77
Any geohelminth
Negative 919 158 (17.2) 1 1
Positive 2744 304 (11.1) 0.60 (0.46–0.78) o0.0001 0.71 (0.55–0.91) 0.007
ORs for A. lumbricoides, T. trichiura, and hookworm were adjusted for the presence of the other two parasites. OR for hookworm is adjusted also for
number of electrical appliances.
All ORs are adjusted for treatment area, age, sex, income, maternal educational level, water source.
 c 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40:1669–1677
1674 P. Endara et alAn important potential limitation of the present study
was the absence of data from two decades previously on
the prevalence of SPT and allergic outcomes in the
communities before the start of ivermectin distribution.
We believe that the prevalence of these outcomes was
unlikely to have been systematically different between
these Afro-Ecuadorian communities because 20 years
ago, these communities were more homogeneous than
they are now given the geographic isolation of the study
area, a similar tropical rain forest environment, and a
shared lifestyle and ethnicity reinforced by contact be-
tween communities by river. Only more recently have
differences started to emerge (see Table 1) caused by the
building of roads and social and environmental changes
associated with the process of modernization [20] that so
far have started to intrude upon untreated more than
treated communities. The differences between treated and
untreated communities observed in Table 1 (e.g. maternal
educational level, number of household electrical appli-
ances and sources of drinking water) indicate a greater
degree of ‘rurality’ in treated communities, a factor that is
considered to be strongly protective against atopy [21].
Such a bias would be expected to reduce rather than
increase the prevalence of SPT among children living in
treated compared with untreated communities. The ﬁnd-
ings that SPT and eczema had a higher prevalence in the
treated communities but asthma prevalence was similar
between treated and non-treated communities are consis-
tent with previous intervention studies: an elevated pre-
valence of SPT [10, 12] and eczema [22] in treated arms
but similar prevalence of asthma in children living in
treated and non-treated arms [12, 13].
Epidemiological studies have shown strong inverse
associations between SPT1 and geohelminth infections
in high-prevalence populations [5–8], and the inverse
associations observed in the present studies are similar to
those reported in previous studies conducted in rural
Ecuador [6, 13, 23]. The inverse associations have been
interpreted to indicate an active suppression of allergen
skin test reactivity by active geohelminth infections [23].
Previous anthelmintic treatment studies have docu-
mented the effects of between 12 and 30 months of
periodic treatments and have provided conﬂicting ﬁnd-
ings: (1) a non-randomized intervention study in Vene-
zuela showed that monthly anthelmintic treatment with
oxantel–pyrantel over 18 months increased the preva-
lence of allergen skin test reactivity to HDM from 17%
to 68% among 94 children with a high prevalence of
infection before treatment [10]; (2) an open-label placebo-
controlled randomized intervention study in Gabon trea-
ted 165 children with a combination of praziquantel and
mebendazole every 3 months for 30 months and showed
that anthelmintic treatment increased the rate of develop-
ing skin sensitivity to HDM compared with the placebo
(hazard ratio 2.51, 95% CI 1.85–3.41) among skin-test-
negative children and the effect appeared to be mediated
partly by reductions in infections with A. lumbricoides
and T. trichiura [11]; (3) a double-blind randomized
controlled trial in Vietnam treated 1566 schoolchildren
in a hookworm-endemic region to receive placebo or
mebendazole/albendazole at 3-monthly intervals and
showed no effect of the intervention on clinical allergy
but evidence of an increased prevalence of allergen skin
test reactivity (OR 1.31, 95% CI 1.02–1.67) [12] and (4) a
cluster-randomized study in Ecuador that allocated
schools to monthly treatments with albendazole or no
treatment showed no effect of treatment on allergen skin
test reactivity or clinical allergy after 12 months of
follow-up of 68 schools (1632 children) [13].
Possible explanations for differences in the effects of
anthelmintic treatment on allergen skin test reactivity
between studies are: (1) difference in treatment period –
the treatment period was much longer in the present study
(15–17 years) compared with the previous negative Ecua-
dorian study (1 year). Periodic anthelmintic treatment
given over 15–17 years may cut transmission levels,
reduce the prevalence of active infections, and attenuate
the development of immune regulatory mechanisms asso-
ciated with chronic infection. The mechanisms by which
chronic geohelminth infections modulate allergen skin
test reactivity are unclear. Enhanced production of IL-10
by lymphocytes stimulated with parasite antigen has been
associated with reduced skin test responses in children
infected with schistosomiasis [24], but not geohelminth
infections [12, 25, 26]. (2) Differences in anthelmintic
drugs – there is no evidence that any of the drugs used
in the intervention studies (albendazole, mebendazole,
praziquantel, oxantel-pyrantel and ivermectin) have di-
rect effects on allergic reactivity but they do have differ-
ing spectrums of activity against geohelminth parasites
[27]. Albendazole given at single doses of 400mg is
extremely effective against A. lumbricoides but has lim-
ited effects on T. trichiura infection [27]. In the present
study, long-term ivermectin had no effect on A. lumbri-
coides prevalence, but had a signiﬁcant impact on
T. trichiura prevalence (treated 31.2% vs. untreated
81.5%). These ﬁndings are consistent with those of pre-
vious studies of the anthelmintic effects of one to four
doses of ivermectin [28–30]. (3) Differences in endemic
geohelminths – the type of geohelminth parasites endemic
in a particular geographic region may be an important
determinant of ﬁndings from different studies [10–13].
The prevalence of A. lumbricoides (55.9%) was similar in
the present study to the previous negative Ecuadorian
study [13], although infection intensities were greater in
the previous study (GM infection intensity 73epg) [13].
The prevalence and infection intensities of T. trichiura
were lower in the previous study (prevalence 55.8%, GM
infection intensity 25epg) [13] compared with untreated
children in the present study, and hierarchical analyses
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SPT1 prevalence was mediated partly by this infection.
A cohort study in urban Salvador in Brazil showed that
infections, particularly high-intensity infections with
T. trichiura during the ﬁrst 3 years of life was associated
with suppression of allergen skin test reactivity later in
childhood and this effect was independent of later
T. trichiura infections [8]. Thus, an explanation for the
effect observed of T. trichiura infection in the present
study may be the effect of treatment in reducing the
prevalence of T. trichiura in early childhood, through
a reduction in community transmission of infection.
Such early effects could attenuate the development of
immune regulatory mechanisms associated with chronic
infection [31].
The effect of long-term ivermectin treatments on recent
eczema symptoms was surprising, and was not associated
with geohelminth infections in schoolchildren. There are
four possible explanations for this observation: (1) data on
eczema symptoms obtained by questionnaire may over-
estimate prevalence where pruritic infections such as
scabies are common. However, because ivermectin is an
extremely effective treatment for scabies [15], the pre-
valence of scabies would be expected to be much higher
among non-treated than treated children and is, therefore,
an unlikely explanation for the greater prevalence of
recent eczema symptoms observed among treated chil-
dren. In fact, childhood infections with ectoparasites such
as scabies and lice (against which ivermectin is also highly
effective [32]), which were ubiquitous before the start of
ivermectin and are now less common (EOEP, unpublished
data) in treated communities; (2) an increased prevalence
of recent eczema symptoms among children living
in treated communities could be caused by impaired
regulation of skin inﬂammation arising from the absence
of regulatory effects in the skin that could be induced
by scabies and lice; (3) effects of anthelmintic treatment
on reducing maternal or early infant geohelminth infec-
tions – a previous intervention study has provided some
evidence that anthelmintic treatment of mothers during
pregnancy may be associated with an increased preva-
lence of eczema in the offspring [22] and (4) pruritus and
rash are common reactions to the microﬁlaricidal effects
of ivermectin on dermal microﬁlariae of O. volvulus [33].
These so-called Mazzotti reactions are self-limiting and
resolve within a few days of treatment, but only occur in
the presence of active O. volvulus infection. It is unlikely
that recent eczema symptoms might have been confused
with such reactions in the present study because transmis-
sion of O. volvulus infection has been interrupted in
all treated study communities for at least 10 years [14],
none of the study children had evidence of dermal micro-
ﬁlariae in previous surveys, and no Mazzotti reactions
were observed in those study communities that were
included in detailed dermatological surveys conducted
in 2004 and 2008 (EOEP, unpublished data). Further,
serological assays to detect exposure to O. volvulus infec-
tion that have been conducted in samples of children from
some of the study communities have been all negative
(EOEP, unpublished data).
In conclusion, the present analysis comparing allergic
parameters between children living in communities that
have received periodic mass treatments with ivermectin
with children from communities that have not received
treatment provides some evidence that long-term anthel-
mintic treatments – in this case 15–17 years, to our
knowledge by far the longest period of continuous treat-
ment so far documented through a real world public
health intervention with high rates of treatment coverage
sustained over many years [14] – may be associated with
an increase in the prevalence of allergen skin test reactiv-
ity and possibly also recent eczema symptoms. The
increase in allergen skin test reactivity, but not eczema
symptoms, was associated with a reduced prevalence of
T. trichiura infection.
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